Cargando…

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM

AIMS: To ensure the integrity of the planned analyses and maximize the clinical utility of the VERIFY study results by describing the detailed concepts behind its statistical analysis plan (SAP) before completion of data collection and study database lock. The SAP will be adhered to for the final pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthews, David R., Paldánius, Päivi M., Stumvoll, Michael, Han, Jackie, Bader, Giovanni, Chiang, YannTong, Proot, Pieter, Del Prato, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771473/ https://www.ncbi.nlm.nih.gov/pubmed/31144427 http://dx.doi.org/10.1111/dom.13800

Ejemplares similares

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin‐metformin combination in newly diagnosed Type 2 diabetes
por: Matthews, D. R., et al.
Publicado: (2019)

Research: Treatment Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trial
por: Del Prato, S, et al.
Publicado: (2014)

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study
por: Vencio, Sérgio, et al.
Publicado: (2021)

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
por: Matthews, David, et al.
Publicado: (2020)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
por: Kozlovski, Plamen, et al.
Publicado: (2017)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Yoo, Soon-Jib, et al.
Publicado: (2021)

Using LOTOS in specifying and verifying the ALICE-DDL protocol
por: Meggyesi, Z, et al.
Publicado: (1997)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin
por: Al Omari, Mousa, et al.
Publicado: (2016)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008)

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Visual analog scale: Verify appropriate statistics
por: Kannan, S., et al.
Publicado: (2015)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
por: Cakirca, Mustafa, et al.
Publicado: (2014)

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
por: Schweizer, Anja, et al.
Publicado: (2012)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis
por: Brath, Helmut, et al.
Publicado: (2017)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
por: Klempfner, Robert, et al.
Publicado: (2012)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study
por: Mohan, Viswanathan, et al.
Publicado: (2021)

Liquid Chromatographic Methods for the Determination of Vildagliptin in the Presence of its Synthetic Intermediate and the Simultaneous Determination of Pioglitazone Hydrochloride and Metformin Hydrochloride
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_59d840gug9qno16425q0u1ecep